Rockingstone Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.33M Buy
3,612
+112
+3% +$114K 1.74% 21
2026
Q1
$3.22M Sell
3,500
-2
-0.1% -$2.03K 1.48% 27
2025
Q4
$3.76M Buy
3,502
+452
+15% +$432K 1.71% 20
2025
Q3
$2.33M Buy
3,050
+357
+13% +$266K 1.15% 35
2025
Q2
$2.1M Sell
2,693
-1,030
-28% -$800K 1.1% 39
2025
Q1
$3.07M Buy
3,723
+635
+21% +$528K 1.38% 30
2024
Q4
$2.38M Buy
3,088
+2,783
+912% +$2.3M 1.05% 37
2024
Q3
$270K Buy
305
+60
+24% +$53.9K 0.13% 90
2024
Q2
$222K Buy
+245
New +$196K 0.11% 101
2023
Q4
Sell
-475
Closed -$255K 117
2023
Q3
$255K Buy
+475
New +$245K 0.14% 106

Other funds holding LLY

Rockingstone Advisors's LLY Position: Q2 2026 in Review

Rockingstone Advisors increased its Eli Lilly (LLY) stake by 3.2% in Q2 2026, buying an estimated $114K and bringing the position to 3,612 shares worth $4.33M. The position accounts for 1.74% of the portfolio, ranked #21.

Rockingstone Advisors first reported a position in LLY in Q3 2023 and has held it in 10 quarters since. 2,247 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Rockingstone Advisors held 3,612 shares of Eli Lilly worth $4.33M as of Q2 2026.
  • Rockingstone Advisors bought 112 Eli Lilly shares in Q2 2026, an estimated $114K.
  • Eli Lilly made up 1.74% of Rockingstone Advisors's portfolio in Q2 2026, its #21 holding.
  • Rockingstone Advisors first reported a position in Eli Lilly in Q3 2023 and has held it in 10 quarters since.
  • 2,247 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Rockingstone Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.